Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06506916 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study of Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis, sponsored by UCB Biopharma SRL.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
- 16
- Study locations
NCT06506916 is a Phase 3 study of Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 90 participants, below the 851-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (89% lower). The trial reports 16 study locations across 7 states.
The verdict
NCT06506916, a Phase 3 study of Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis, is actively recruiting participants, sponsored by UCB Biopharma SRL.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).
Conditions Studied
Interventions
- DRUG bimekizumab
Study Locations (16)
Other
- Ps0039 40515 - Berlin
- Ps0039 40287 - Frankfurt am Main
- Ps0039 40072 - Freiburg im Breisgau
- Ps0039 40775 - Witten
- Ps0039 40347 - Lodz
- Ps0039 40757 - Poznan
- Ps0039 40625 - Warsaw
- Ps0039 40761 - Warsaw
- Ps0039 40773 - Wroclaw
California
- Ps0039 50162 - Fountain Valley
- Ps0039 50642 - Santa Monica
Alabama
- Ps0039 50140 - Birmingham
Florida
- Ps0039 50283 - Tampa
Michigan
- Ps0039 50110 - Ann Arbor
New York
- Ps0039 50643 - Rochester
Pennsylvania
- Ps0039 50491 - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-07-29 |
| Est. Completion | 2028-03-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06506916
The ClinicalTrials.gov registry entry for NCT06506916 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 851-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (89% lower). The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Psoriatic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which bimekizumab is the first listed.
NCT06506916 reports 16 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06506916 about?
NCT06506916 is a clinical study titled "A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis". The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biop...
What is the current status of trial NCT06506916?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2024-07-29. Estimated completion is 2028-03-14.
What conditions does trial NCT06506916 study?
This clinical trial studies the following conditions: Psoriatic Arthritis, Moderate to Severe Plaque Psoriasis.
What interventions are being tested in trial NCT06506916?
The interventions under investigation include: bimekizumab (DRUG).
Who is sponsoring clinical trial NCT06506916?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06506916 being conducted?
This trial has 16 study locations across Alabama, California, Florida, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RECRUITING · Phase 3
-
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
RECRUITING · Phase 3
-
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.